Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 3565

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 3565
---
    ●
    our
    failure to commercialize our product candidates, if approved;

    ●
    additions
    or departures of key scientific or management personnel;

    ●
    unanticipated
    serious safety concerns related to the use any of our product candidates;

    ●
    introduction
    of new products or services offered by us or our competitors;

    ●
    announcements
    of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;

    ●
    our
    ability to effectively manage our growth;

    ●
    actual
    or anticipated variations in quarterly operating results;

    ●
    our
    cash position;

    ●
    our
    failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;

    ●
    publication
    of research reports about us or our industry, or product candidates in particular, or positive or negative recommendations or withdrawal
    of research coverage by securities analysts;

    ●
    changes
    in the market valuations of similar companies;

    ●
    changes
    in the structure of the healthcare payment systems;

    ●
    overall
    performance of the equity markets;

    ●
    sales
    of our common stock and public warrants by us or our stockholders in the future;

    ●
    trading
    volume of our common stock and public warrants;

    ●
    changes
    in accounting practices;

    ●
    ineffectiveness
    of our internal controls;

    ●
    disputes
    or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection
    for our technologies;

123

    ●
    significant
    lawsuits, including patent or stockholder litigation;

    ●
    general
    political and economic conditions,; and

    ●
    other
    events or factors, many of which are beyond our control.

In
addition, the stock market in general, and the market for biopharmaceutical companies in particular, have experienced extreme price and
volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market
and industry factors, as well as local or global socio-economic and political factors, including the conflict between Russia and Ukraine,
may negatively affect the market price of our common stock, regardless of our actual operating performance. If the market price of our
common stock and warrants does not exceed the price you paid for them,